Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 14/20 | 0.59 |
| ▸ | HDAC2 | Q92769 | 11/20 | 0.59 |
| ▸ | HDAC3 | O15379 | 10/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.58 |
| ▸ | CCNC | P24863 | 1/20 | 0.54 |
| ▸ | CDK8 | P49336 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8157053 | 0.89 | HDAC1 (0.55) | HDAC1HDAC2HDAC3KCNH2MAPK1 | |
| SCHEMBL5225255 | 0.86 | KCNH2 (0.76) | HDAC1HDAC2HDAC3KCNH2 | |
| SCHEMBL2828860 | 0.81 | HDAC1 (0.74) | HDAC1HDAC2HDAC3KCNH2CCNC | |
| SCHEMBL17529213 | 0.79 | HDAC1 (0.47) | HDAC1HDAC2HDAC3KCNH2MAPK1 | |
| SCHEMBL5225051 | 0.79 | HDAC3 (0.77) | HDAC1HDAC2HDAC3KCNH2 | |
| Hydrochloric Acid SCHEMBL5226156 | 0.78 | HDAC3 (0.76) | HDAC1HDAC2HDAC3KCNH2 | |
| SCHEMBL5224561 | 0.78 | HDAC2 (0.76) | HDAC1HDAC2HDAC3KCNH2 | |
| SCHEMBL5228516 | 0.77 | HDAC1 (0.53) | HDAC1HDAC2HDAC3 | |
| SCHEMBL6339376 | 0.77 | HDAC1 (0.54) | HDAC1HDAC2HDAC3KCNH2 | |
| SCHEMBL2404792 | 0.76 | HDAC1 (0.48) | HDAC1HDAC2HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016020307-A1 | NOVEL COMPOUNDS FOR USE IN COGNITION IMPROVEMENT | FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADA (ES) | 2016-02-11 | — | — | WO | disclosed |
| EP-1501508-B1 | INHIBITORS OF HISTONE DEACETYLASE | ASTRAZENECA AB (SE) | 2007-02-21 | — | — | EP | disclosed |
| US-20050222410-A1 | Inhibitors of histone deacetylase | ASTRAZENECA AB (SE) | 2005-10-06 | — | — | US | disclosed |
| EP-1501508-A1 | INHIBITORS OF HISTONE DEACETYLASE | Astrazeneca AB (SE) | 2005-02-02 | — | — | EP | disclosed |
| WO-2003092686-A1 | INHIBITORS OF HISTONE DEACETYLASE | ASTRAZENECA AB (SE) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222410-A1 | Inhibitors of histone deacetylase | HDAC1, HDAC3, HDAC11 | HDAC1 1/4885HDAC2 4/4885HDAC3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.